system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: OBJECTIVE, METHODS, RESULTS. Meshes: Anti-Inflammatory Agents, Antioxidants, Blood Sedimentation, C-Reactive Protein, Cardiovascular Diseases, Cilostazol, Diabetes Mellitus, Type 2, Female, Glutathione, Glycated Hemoglobin A, Humans, Hypertension, Inflammation, Leukocyte Count, Male, Malondialdehyde, Middle Aged, Oxidative Stress, Risk Assessment, Risk Factors, Serum Albumin, Tetrazoles, Time Factors, Treatment Outcome.
user
Does cilostazol reduce inflammatory burden and oxidative stress in hypertensive type 2 diabetes mellitus patients? Context: Inflammation and oxidative stress cause genesis and progression of atherosclerosis in diabetes. This study aimed to assess effects of Cilostazol on these factors in hypertensive type 2 diabetic patients. In randomized, open, add-on preventive controlled clinical trial design, 60 hypertensive type 2 diabetics aged >or=45 years were evaluated clinically and for total leukocyte count, erythrocyte sedimentation rate, serum albumin, serum hsC-reactive protein, plasma malondialdehyde, blood reduced glutathione and HbA1c levels. After informed consent, 30 patients received Cilostazol (100mg) twice daily orally as add-on therapy. At 1 month follow-up, 26 patients in control group and 22 patients in Cilostazol group completed the trial and particular parameters were re-evaluated. The mean age and duration of diabetes were 55+/-7 years and 8+/-6 years, respectively. At follow-up, the Cilostazol group showed significant (p<0.001) decrease in hsC-reactive protein (23.6%), erythrocyte sedimentation rate (38.7%), total leukocyte count (12.6%), plasma malondialdehyde (17.6%), HbA1c (0.17%, p=0.002) and increase in serum albumin (11.9%), blood reduced glutathione (3.5%) from baseline. UKPDS 10 years risk of coronary heart disease decreased by 6% (p=0.002). The control group did not show significant improvement in inflammatory profile, oxidative status and HbA1c.
assistant
Inflammatory and oxidative stress is high in hypertensive type 2 diabetic patients. Cilostazol reduces these factors as well as coronary heart disease risk in diabetes mellitus. Final Decision: yes